Aigen Investment Management LP Invests $868,000 in BioMarin Pharmaceutical Inc. $BMRN

Aigen Investment Management LP bought a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 4th quarter, Holdings Channel reports. The firm bought 14,598 shares of the biotechnology company’s stock, valued at approximately $868,000.

Several other institutional investors have also recently made changes to their positions in BMRN. Norges Bank bought a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth about $447,572,000. Capital Research Global Investors increased its stake in BioMarin Pharmaceutical by 547.5% in the 3rd quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock worth $137,436,000 after buying an additional 2,145,717 shares during the period. Viking Global Investors LP increased its stake in BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after buying an additional 1,488,552 shares during the period. Dimensional Fund Advisors LP increased its stake in BioMarin Pharmaceutical by 48.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock worth $197,405,000 after buying an additional 1,076,568 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in BioMarin Pharmaceutical by 312.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,419,067 shares of the biotechnology company’s stock worth $84,335,000 after buying an additional 1,074,929 shares during the period. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $55.95 on Monday. The firm’s 50 day moving average price is $54.35 and its 200-day moving average price is $56.43. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $66.28. The company has a market cap of $10.81 billion, a P/E ratio of 40.84, a PEG ratio of 0.43 and a beta of 0.25.

Insider Activity

In other news, EVP Gregory R. Friberg sold 3,281 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $53.85, for a total value of $176,681.85. Following the transaction, the executive vice president owned 51,818 shares of the company’s stock, valued at $2,790,399.30. The trade was a 5.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BMRN has been the topic of several recent analyst reports. HC Wainwright reduced their price target on shares of BioMarin Pharmaceutical from $55.00 to $50.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. Royal Bank Of Canada restated a “sector perform” rating and issued a $66.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, May 5th. Citigroup started coverage on shares of BioMarin Pharmaceutical in a report on Tuesday, May 19th. They issued a “buy” rating and a $75.00 price target for the company. Bank of America reduced their price target on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Finally, Guggenheim reduced their price target on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $88.67.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.